Healthy adult
Conditions
Interventions
Administration of a PET tracer.
Sponsors
Integrated Health Science Co., Ltd.
Hamamatsu Medical Photonics Foundation, Hamamatsu Medical Imaging Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Aged 20 to under 65 2. A body weight of at least 50 kg but less than 85 kg, and a BMI of at least 18.5 but less than 26.5.
Exclusion criteria
Exclusion criteria: 1.Individuals with serious diseases affecting organs such as the liver, kidneys, heart, blood, or blood vessels. 2.Individuals who have taken or used any medicinal products, quasi-drugs, or health foods (including dietary supplements) within 7 days prior to administration of the investigational product. 3.Individuals who habitually consume asetic acid beverages or supplements, or who have taken such beverages or supplements within 1 month prior to administration of the investigational product. 4.Individuals who are habitual heavy drinkers (20 g or more of pure alcohol per day) or who have engaged in excessive alcohol consumption (40 g or more per day) within the past 7 days. 5.Individuals who are current smokers. 6.Individuals with a history of drug allergy or food allergy. 7.Individuals who are currently participating in another clinical study, or who have participated in another clinical study in the past, and for whom less than 4 months have passed since the last administration of the investigational drug. 8. Individuals who have donated 200 mL or more of blood within the past 1 month, or 400 mL or more of blood within the past 3 months. 9.Individuals who have participated in another PET study within the past 1 year. 10.Individuals with drug dependence or alcohol dependence. 11.Individuals who have received a vaccine for influenza, COVID-19, or other vaccines within 2 weeks prior to administration of the investigational drug. 12.Individuals judged as inappropriate for participation by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time-course quantitative measurements of [2-11C]acetate uptake in each organ and regions of interest, and changes in time-course quantitative [2-11C]acetate uptake in brain regions associated with task-related brain activity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Temporal changes in [2-11C]acetate uptake in head muscles and cervicocranial tissues during rest and brain activation periods. | — |
Countries
Japan
Contacts
Public ContactKyosuke Watanabe
Integrated Health Science Co., Ltd. Research Division
Outcome results
None listed